Search results
Sarepta Duchenne gene therapy wins broader use from FDA
BioPharma Dive via Yahoo Finance· 23 hours agoThe approval makes Elevidys available to most Duchenne patients at least 4 years of age, despite...
Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Chardan Capital
ETF DAILY NEWS· 3 days agoChardan Capital reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report issued on Tuesday morning, Benzinga reports. Chardan Capital currently ...
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.1%
ETF DAILY NEWS· 6 days agoTaysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) traded down 4.1% on Friday . The company traded as low as $3.95 and last traded at $4.00. 191,240 shares were traded during trading ...
Sarepta’ stock soars 38% after FDA expands approval for DMD drug
Market Watch· 5 hours agoThere are about 15,000 cases in the U.S., according to the Muscular Dystrophy Association. The FDA...
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial By Proactive...
Investing.com· 21 hours agoGilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm...
This little-known biotech stock is primed to surge nearly 50%, Canaccord says
CNBC· 1 day agoThe financial firm stood by its buy rating on the biopharma name but raised its price target by 6%...
Weight loss drug contender Zealand Pharma jumps 23% on trial results
CNBC· 6 hours agoShares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high...
Pharma Investing Is All About Service Now. The Patent Cliff Era Is Ending.
Barrons.com· 7 days agoMany personalized therapies leverage a range of technologies accessible to various companies. As a...
The Best LED Face Masks To Improve Wrinkles And Acne, According To Dermatologists
Women's Health via Yahoo News· 1 day agoThe best FDA-approved LED light therapy face masks, per dermatologists and editors, have benefits...
OS Therapies Inc. Plans $8 Million IPO for June 20th (OSTX)
ETF DAILY NEWS· 6 days agoOS Therapies Inc. (OSTX) plans to raise $8 million in an IPO on Thursday, June 20th, IPO Scoop reports. The company will issue 2,000,000 shares at a price of $4.00 per share. OS Therapies Inc. has a market cap of $82.3 million.